1. Xiang H, Chan AG, Ahene A, Bellovin DI, Deng R, Hsu AW, Jeffry U, Palencia S, Powers J, Zanghi J, Collins H. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021 Jan-Dec;13(1):1981202. doi: 10.1080/19420862.2021.1981202. PMID: 34719330; PMCID: PMC8565817.
2. Rosato B, Ranieri D, Nanni M, Torrisi MR, Belleudi F. Role of FGFR2b expression and signaling in keratinocyte differentiation: sequential involvement of PKCδ and PKCα. Cell Death Dis. 2018 May 1;9(5):565. doi: 10.1038/s41419-018-0509-x. PMID: 29752438; PMCID: PMC5948219.
3. Ahmadvand N, Lingampally A, Khosravi F, Vazquez-Armendariz AI, Rivetti S, Jones MR, Wilhelm J, Herold S, Barreto G, Koepke J, Samakovlis C, Carraro G, Zhang JS, Al Alam D, Bellusci S. Fgfr2b signaling is essential for the maintenance of the alveolar epithelial type 2 lineage during lung homeostasis in mice. Cell Mol Life Sci. 2022 May 19;79(6):302. doi: 10.1007/s00018-022-04327-w. PMID: 35587837; PMCID: PMC9120111.